Remdesivir becomes first drug to be fully approved for COVID-19 by US: All you need to know
Team Udayavani, Oct 23, 2020, 1:13 PM IST
The US Food and Drug Administration on Thursday approved Gilead’s antiviral drug remdesivir for treating patients hospitalised with COVID-19, making it the first and only drug approved for the disease in the US.
Remdesivir was given to President Donald Trump this month when he was diagnosed with COVID-19. It was originally developed as a treatment for Ebola and Hepatitis C.
Remdesivir was developed to treat Ebola disease caused by an RNA virus. Now, Gilead discovered that the drug has antiviral activity in vitro against pathogens that cause MERS and SARS, which are coronaviruses and structurally similar to SARS-CoV-2 that causes COVID-19, an RNA virus.
Remdesivir is thought to interfere with the mechanism that certain viruses, including the new coronavirus, use to make copies of themselves.
According to FirstPost, Remdesivir is a nucleoside analogue. Studies show that it competes with ATP (adenosine triphosphate) during the production of viral RNA.
Viruses are intracellular parasites. Once they get inside healthy cells, they use the machinery and materials from these cells to make copies of their own nucleic acid. RNA or ribonucleic acid is the genetic material of SARS-CoV-2.
Every RNA is made of a series of four nucleotide bases arranged in various ways to code for specific characters or make specific proteins. These bases include ATP, GTP, CTP and UTP.
An enzyme called RNA polymerase makes new RNA copies which are then used to make new viruses. Remdesivir, when it gets integrated in place of ATP during the formation of RNA, completely halts the replication process. No replication means no new RNA and no new virus.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Centre asks states to take steps to reopen medical colleges from or before Dec 1
New COVID-19 guidelines for states issued; to be effective from Dec 1
Siddaramaiah slams Yediyurappa govt over appointments to statutory bodies
Related Articles More
Diabetic eye disease associated with five-fold risk of severe COVID-19: Study
How did a dosing error lead to Oxford vaccine’s 90% effectiveness?
COVID-19 vaccine: India Aatmanirbhar for syringes, says industry
Are dining tents a safe way to eat out during the pandemic?
COVID-19: One crore frontline healthcare workers identified to receive vaccine in first phase
Centuries-old Tuluva ritual of ‘Bhoomipuje Gaddekori’ still performed at Palthadi Village in Puttur
A bike rider dies in a lorry crash : The scene of the accident was captured on CCTV
Moodbidri: Four people drowned in Shambhavi river
1348 new vented dams in K’taka’s coastal districts: J.C. Madhu Swamy
Karavali gets introduced to Japanese ‘kokedama’ art
Trade unions to go on nationwide strike on Nov 26
K’taka COVID-19 update: 1630 new cases, 1333 discharges, 19 deaths on Nov 24
Hubballi: Police crack murder case within 24 hours; 2 arrested
Iran diplomat on trial in France over plot to bomb opponents
Cabinet approves MoU between BRICS nations on sports and physical culture